SCHEMBL2944356

SCHEMBL2944356

COc1cccc(-c2nncc3cc(-c4cc(C(N)=O)ccc4C)ccc23)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.54
KIT P10721 7/20 0.54
MAPK9 P45984 5/20 0.54
MAPK10 P53779 2/20 0.54
KDR P35968 6/20 0.51
LCK P06239 5/20 0.51
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ABL1 P00519 1/20 0.40
LYN P07948 1/20 0.40
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
CHUK O15111 1/20 0.38
INSR P06213 1/20 0.38
MAPK8 P45983 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
FYN P06241 1/20 0.38
CYP3A4 P08684 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2952505 0.93 MAPK14 (0.58) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2948437 0.85 MAPK14 (0.70) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2945984 0.85 MAPK14 (0.59) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2944218 0.84 MAPK14 (0.50) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2954403 0.83 MAPK14 (0.54) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2945502 0.83 MAPK14 (0.51) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2956912 0.82 MAPK14 (0.54) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2948078 0.82 MAPK14 (0.60) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2946091 0.81 MAPK14 (0.51) MAPK14KITMAPK9MAPK10KDR
SCHEMBL2949665 0.81 MAPK14 (0.57) MAPK14KITMAPK9MAPK10KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP claimed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US claimed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP claimed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO claimed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US claimed
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 MAPK14 293/4885KIT 1977/4885MAPK9 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.